共 50 条
- [31] Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphomaCANCER SCIENCE, 2011, 102 (02) : 432 - 438Tobinai, KenseiOgura, MichinoriKobayashi, YukioUchida, ToshikiWatanabe, TakashiOyama, TakashiMaruyama, DaiSuzuki, TatsuyaMori, MasakazuKasai, MasanobuCronier, DamienWooldridge, James E.Koshiji, Minori
- [32] Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma PatientsCLINICAL CANCER RESEARCH, 2010, 16 (20) : 5067 - 5078Jacobs, Joannes F. M.Punt, Cornelis J. A.Lesterhuis, W. JoostSutmuller, Roger P. M.Brouwer, H. Mary-lene H.Scharenborg, Nicole M.Klasen, Ina S.Hilbrands, Luuk B.Figdor, Carl G.de Vries, I. Jolanda M.Adema, Gosse J.
- [33] A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular responseBRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) : 81 - 88Foran, JMGupta, RKCunningham, DPopescu, RAGoldstone, AHSweetenham, JWPettengell, RJohnson, PWMBessell, EHancock, BSummers, KHughes, JRohatiner, AZSLister, TA
- [34] Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphomaJOURNAL OF DERMATOLOGY, 2024, 51 (08): : 1037 - 1049Hirai, YojiSakurai, JunYoshida, ShihoKikuchi, TakashiMitsuhashi, ToshiharuMiyake, TomokoFujimura, TakuAbe, RiichiroFujikawa, HirokiBoki, HikariSuga, HirakuShibata, SayakaMiyagaki, TomomitsuShimauchi, TakatoshiKiyohara, EijiKawakami, YoshioMorizane, Shin
- [35] QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) TREATED WITH ANTI-CCR4 MONOCLONAL ANTIBODY MOGAMULIZUMAB VS VORINOSTAT: RESULTS OF THE STUDY PHASE 3 MAVORICHAEMATOLOGICA, 2018, 103 : 18 - 18Caballero Barrigon, D.Ortiz Romero, P.
- [36] Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's LymphomaBLOOD, 2011, 118 (21) : 1584 - 1584Christian, BethAlinari, LapoJones, Jeffrey A.Benson, Don M., Jr.Flynn, Joseph M.Porcu, PierluigiLustberg, Mark E.Phelps, MitchellPoi, MingChung, DianaQuinion, CarlByrd, John C.Wegener, WilliamGoldenberg, David M.Baiocchi, Robert A.Blum, Kristie A.
- [37] Phase I study of KW-0761, a humanized anti-CCR4 antibody, in patients (Pts) with relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL): Preliminary resultsBLOOD, 2007, 110 (11) : 194B - 194BUike, NaokumiTsukasaki, KunihiroUtsunomiya, AtaeTobinai, KenselMorishima, YasuoUozumi, KimiharuTomonaga, MasaoMatsushima, KojiShitara, KnyaAkinaga, ShiroUeda, Ryuzo
- [38] Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results.BLOOD, 2008, 112 (11) : 370 - 371Yamamoto, KazuhitoTobinai, KenseiUtsunomiya, AtaeTsukasaki, KunihiroUike, NaokuniUozumi, KimiharuTomonaga, MasaoMatsushima, KojiShitara, KenyaAkinaga, ShiroUeda, Ryuzo
- [39] Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-HLA-DR monoclonal antibody Remitogen™ (Hu1D10).BLOOD, 2001, 98 (11) : 244B - 244BLink, BKWang, HByrd, JCLeonard, JPDavis, TAFlinn, IHall, WCTurner, JFBowles, JShannon, MLevitt, DWeiner, GJ
- [40] Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trialsANNALS OF ONCOLOGY, 2024, 35 : S519 - S519Herbel, N.Ouali, K.Danlos, F-X.Massard, C. P.Goldschmidt, V.Michot, J-M.Laparra, A.Bernard-Tessier, A.Gazzah, A.Bahleda, R.Hollebecque, A.Henon, C.Postel-Vinay, S.Loriot, Y.Ribrag, V.Marabelle, A.Fizazi, K.Aix, S. PonceChampiat, S.Baldini, C.